The results as described by Mr. West were positive, and he thinks monoclonal antibody infusion therapy is a viable alternative for fighting COVID as we advance.
Chris Hayes maligns the monoclonal antibody treatment as something that "Big Pharma" sells straight to patients, asking for $2000 in return.
Christina Pushaw corrected him by pointing out to Hayes that "vaccinated people need monoclonal antibodies too."
In addition, both the COVID vaccine and antibodies are "free" to patients while simultaneously costing "the federal government (taxpayers) billions, but no one has to pay 2k a pop for mAb treatment in Florida."
Hayes isn't the only one. People like Kevin Kruse and Max Kennerly played into the idea that Pfizer themselves aren't a "Big Pharma" company.
Again, the spokesperson for Florida Governor DeSantis states outright that "both mAb and vaccine are free to patients."
Pushaw doubled down after the fact, reiterating "40-60 percent of patients at the MAB treatment sites in Florida (depending on location) were vaccinated and had breakthrough cases."
It was late last month that Florida Governor DeSantis triumphantly got a supply of COVID antibody doses, Sotrovimab, directly from the manufacturer.
The Biden administration had previously chosen to buy up Regeneron's antibodies in a last-ditch attempt to control the supply at a federal level.
Meanwhile, Trident Medical Center announced that 97% of patients battling COVID-19 could recover at home after getting monoclonal antibody infusion therapy.
The center announced that over 1,200 Lowcountry and Upstate patients who were newly diagnosed with the coronavirus got the treatment to reduce the virus's symptoms.
"Hospital officials say the treatment accomplished its intended purpose - help reduce COVID-related hospitalizations," Trident officials announced.
The hospital has created its monoclonal antibody clinic with the treatment available for patients at more locations in the Lowcountry.
Bamlanivimab, a monoclonal antibody infusion therapy, is a type of treatment for non-hospitalized patients with mild or moderate cases of COVID-19 aimed to prevent patients from becoming hospitalized patients.
The therapy for emergency-use authorization from the U.S. Food and Drug Administration on Nov. 9, and they say the treatment has a 98% effective rate in preventing hospitalizations.